Name (Synonyms) | Correlation | |
---|---|---|
drug220 | COVID-19 infection Wiki | 0.71 |
drug535 | Hydroxychloroquine and Ivermectin Wiki | 0.71 |
drug215 | COVID-19 barrier box Wiki | 0.71 |
drug534 | Hydroxychloroquine and Azithromycin Wiki | 0.50 |
drug239 | Camostat Mesilate Wiki | 0.35 |
drug505 | Hydroxychloroquine Wiki | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
D012216 | Rheumatic Diseases NIH | 1.00 |
D012213 | Rheumatic Fever NIH | 0.71 |
D001167 | Arteritis NIH | 0.50 |
D025241 | Spondylarthritis NIH | 0.50 |
D011111 | Polymyalgia Rheumatica NIH | 0.50 |
D013700 | Giant Cell Arteritis NIH | 0.50 |
D015535 | Arthritis, Psoriatic NIH | 0.41 |
D001327 | Autoimmune Diseases NIH | 0.41 |
D008180 | Lupus Erythematosus, Systemic NIH | 0.35 |
D001168 | Arthritis NIH | 0.27 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012089 | Arteritis HPO | 0.50 |
HP:0002960 | Autoimmunity HPO | 0.41 |
HP:0002725 | Systemic lupus erythematosus HPO | 0.35 |
HP:0001369 | Arthritis HPO | 0.27 |
There are 2 clinical trials
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusionDescription: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusionDescription: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.